{'fraction_non_alphanumeric': 0.02040816326530612, 'fraction_numerical': 0.04672395273899033, 'mean_word_length': 5.46875, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Correlation analysis of microRNA155 and microRNA29 with T2DM and prediction and verification of target genes.

BACKGROUND
MicroRNA155 and microRNA29 are reported to inhibit glucose metabolism in some cell and animal models, but no evidence from susceptible populations that examines the relationship between microRNA155 or microRNA29 and T2DM currently exists. Moreover, target genes regulated by microRNA155 and microRNA29 that affect glucose and lipid metabolism remain unknown.


METHODS
Human subjects were divided into normal weight (NC, n = 72), obesity (Ob, n = 120), and type 2 diabetes (T2DM, n = 59) groups. The contents of microRNA155 and microRNA29 abundance in serum was measured, and candidate genes potentially related to glucose and lipid metabolism targeted by either microRNA155 or microRNA29 were screened. Over-expression of microRNA155 and microRNA29 in HepG2 cells was used to verify candidate gene expression and measure the effects on glucose and lipid metabolism.


RESULTS
Serum levels of microRNA155 and microRNA29 display a significant increase in Ob and T2DM individuals compared with NC individuals. Identified target genes for microR155 were MAPK14, MAP3K10, DUSP14, and PRKAR2B. Identified target genes for microRNA29 were PEX11A and FADS1. Over-expression of microRNA155 or microRNA29 in HepG2 cells was found to down-regulate the expression of identified target genes and result in inhibition of triglyceride synthesis and glucose incorporation .


CONCLUSIONS
MicroRNA155 and microRNA29 significant higher in T2DM patients compared to the control patients, and its levels were also positively correlated with fasting plasma glucose levels, and over-expression of microRNA155 or microRNA29 were found to down-regulate glucose and lipid metabolism target genes and reduce lipid synthesis and glucose incorporation in HepG2 cells.